文献速递乳腺癌放疗

乳腺癌病理完全缓解后放疗降阶梯:真实世界与模拟数据整合分析

Radiation Therapy De-escalation in Breast Cancer Patients With Pathologic Complete Response: An Integrated Analysis Using Real-World and Simulated Data.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-05-21

该整合分析结合真实世界证据、临床试验数据与模拟扩展,评估新辅助化疗后达病理完全缓解(pCR)并接受保乳手术的乳腺癌患者,辅助放疗与不放疗的长期总生存差异。结果显示放疗带来的OS获益较小,支持在生物学行为良好且治疗反应优异的亚组中进一步研究放疗降阶梯。

要点

  • pCR患者中辅助放疗的OS绝对获益较小,支持选择性使用放疗。
  • 局部区域复发风险与复发时间分布影响OS获益的估计。
  • 需前瞻性随机试验验证pCR患者放疗降阶梯的可行性。

核心结论

  • 新辅助化疗后达pCR的患者中,辅助放疗的预期OS获益较小,支持放疗降阶梯的进一步研究。

研究设计与样本

  • 整合分析结合真实世界证据、临床试验数据与模拟扩展,评估pCR(ypT0 ypN0)后保乳手术患者放疗与不放疗的长期OS。
  • 模型输入来自已发表试验、观察性队列和癌症登记数据。

主要发现

  • I期患者5年LRR放疗3.0% vs 不放疗7.5%,对应20年OS 85.6% vs 84.0%,绝对差1.6%,需>12,000例达80%把握度。
  • II-III期患者5年LRR 3.0% vs 10.5%,对应20年OS 81.6% vs 78.3%,差异3.3%,需约3800例达足够把握度。
  • OS治疗效应在≥65岁年龄组和三阴性亚型中一致。

关键数值与推荐

  • pCR定义为新辅助化疗后ypT0 ypN0。
  • 评估范围涵盖不同局部区域复发风险和复发时间分布。

临床怎么用

  • 可将病理反应纳入放疗决策框架,对反应优异且生物学行为良好者考虑选择性省略放疗。
  • 需前瞻性随机试验验证后再常规改变实践。

局限性

  • 研究为整合分析与模拟扩展,非前瞻性随机试验。
  • 需前瞻性随机试验验证 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Advances in neoadjuvant chemotherapy (NAC) have markedly increased pathologic complete response (pCR) rates in breast cancer, prompting re-evaluation of the need for adjuvant radiation therapy (RT) in patients with excellent treatment response. The NSABP B-51 trial showed no survival benefit from regional nodal irradiation in patients achieving nodal pCR after NAC; whole-breast RT was still routinely delivered irrespective of breast response. Thus, the potential to safely omit RT in patients achieving breast pCR remains uncertain. METHODS AND MATERIALS: We conducted an integrated analysis combining real-world evidence, clinical trial data, and simulated extensions to evaluate long-term overall survival (OS) with versus without adjuvant RT in patients achieving pCR (defined as ypT0 ypN0) after NAC and breast-conserving surgery. Model inputs were derived from published trials, observational cohorts, and cancer registry data. We assessed OS across a range of local-regional recurrence (LRR) risks and time-to-recurrence distributions reflective of contemporary clinical practice. RESULTS: RT was associated with small OS gains across stages. For stage I disease, 5-year LRR rates of 3.0% with RT versus 7.5% without RT corresponded to 20-year OS of 85.6% and 84.0%, respectively (absolute difference 1.6%), requiring >12,000 patients for 80% power. For stage II to III disease (5-year LRR 3.0% vs 10.5%), 20-year OS was 81.6% vs 78.3%, respectively (difference 3.3%), requiring ∼3800 patients for adequate power. Treatment effects on OS were consistent across age groups (≥65 years) and in the triple-negative subtype. CONCLUSIONS: Among patients achieving pCR after NAC, the projected OS benefit from adjuvant RT appears small. This supports efforts toward more selective RT use and suggests that RT de-escalation warrants further investigation in subgroups with favorable biology and excellent treatment response. These findings reinforce the need for response-adapted decision frameworks and the incorporation of pCR into future RT guidelines. As treatment becomes increasingly personalized, integrating pathologic response into RT decision-making may reduce treatment burden without compromising outcomes. Prospective randomized trials are needed to validate these findings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wang J, Ning J, Shaitelman SF, et al. Radiation Therapy De-escalation in Breast Cancer Patients With Pathologic Complete Response: An Integrated Analysis Using Real-World and Simulated Data. Int J Radiat Oncol Biol Phys. 2026. PMID: 42173325. doi:10.1016/j.ijrobp.2026.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。